TBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Telesis Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $29.54 Mil. Telesis Bio's Total Assets for the quarter that ended in Dec. 2023 was $70.41 Mil. Therefore, Telesis Bio's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.42.
The historical rank and industry rank for Telesis Bio's Equity-to-Asset or its related term are showing as below:
During the past 5 years, the highest Equity to Asset Ratio of Telesis Bio was 0.78. The lowest was -0.95. And the median was 0.42.
The historical data trend for Telesis Bio's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telesis Bio Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Equity-to-Asset | -0.19 | -0.95 | 0.78 | 0.57 | 0.42 |
Telesis Bio Quarterly Data | |||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.57 | 0.41 | 0.49 | 0.44 | 0.42 |
For the Medical Devices subindustry, Telesis Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Telesis Bio's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Telesis Bio's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Telesis Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 29.538 | / | 70.411 | |
= | 0.42 |
Telesis Bio's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as
Equity to Asset (Q: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 29.538 | / | 70.411 | |
= | 0.42 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telesis Bio (NAS:TBIO) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Telesis Bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Gregory J. Herrema | director | 355 RIVER OAKS PARKWAY, SAN JOSE CA 95134 |
Marijn E Dekkers | 10 percent owner | GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210 |
Novalis Lifesciences Investments Ii Gp, Llc | 10 percent owner | 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842 |
Novalis Lifesciences Investments Ii, L.p. | 10 percent owner | 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842 |
Broadoak Fund Iv, Llc | 10 percent owner | 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814 |
William Snider | director, 10 percent owner | 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814 |
Paul M Meister | director, 10 percent owner | 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862 |
Rob Cutler | officer: Chief Legal Officer | C/O TELESIS BIO, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121 |
Daniel Glenn Gibson | officer: Chief Technology Officer | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121 |
Todd Robert Nelson | director, 10 percent owner, officer: President & CEO | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121 |
Eric Eugene Esser | officer: Chief Operating Officer | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121 |
Annette Tumolo | director | C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Northpond Ventures Gp, Llc | 10 percent owner | 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814 |
Northpond Ventures Gp Ii, Llc | 10 percent owner | 7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814 |
Northpond Ventures Ii, Lp | 10 percent owner | 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814 |
From GuruFocus
By sperokesalga sperokesalga • 06-08-2023
By sperokesalga sperokesalga • 03-21-2023
By Marketwired • 11-03-2023
By sperokesalga sperokesalga • 05-11-2023
By sperokesalga sperokesalga • 06-05-2023
By sperokesalga sperokesalga • 04-27-2023
By Marketwired • 08-03-2023
By sperokesalga sperokesalga • 05-15-2023
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 05-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.